Tularik announced after Monday's close that the U.S. Food and Drug Administration has green-lighted the design of what could be the final clinical tests for the South San Francisco-based biotech's liver cancer drug, T67.
Last year MediGene, a German biotech firm, got approval from the FDA for U.S. marketing of an ointment extracted from green tea leaves to treat genital warts.